Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 459.99k Dec 31, 2025 2.18% 699,190 VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund 149.62k Dec 31, 2025 0.71% 227,425 Fidelity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results